预约演示
更新于：2025-04-14
Diclofenac Sodium
双氯芬酸钠
更新于：2025-04-14
概要
基本信息
简介双氯酚酸钠是苯乙酸衍生物，是一种非甾体抗炎药（NSAID），具有镇痛、抗炎和解热作用。和其他NSAIDs一样，双氯酚酸钠的作用机制尚未完全理解，但涉及抑制环氧化酶（COX-1和COX-2）。FDA于1988年7月28日批准双氯酚酸钠（VOLTAREN ）上市，其原产公司为Ciba-Geigy公司，现已并入诺华。这种药物已经长期用于管理多种疼痛症状，并且有处方和非处方制剂 |
药物类型 小分子化药 |
别名 Diclfenac Sodium、Diclofanac Sodium、DICLOFENAC + [119] |
靶点 |
作用方式 抑制剂 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H11Cl2NNaO2 |
InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N |
CAS号15307-79-6 |
关联
347
项与 双氯芬酸钠 相关的临床试验NCT06693648
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 in the Treatment of Pain and Symptoms of Knee Osteoarthritis
NCT06905561
Topical Diclofenac for Prevention of Radiation-induced Dermatitis: A Single-center, Randomized Controlled Trial
CTRI/2024/11/076121
A Randomized Controlled Clinical Trial for Vednasthapan (Analgesic) Effect of Ashoka (Saraca asoca) Ghan Vati in Comparison with Diclofenac Sodium in Post-operative Pain. - NIL
100 项与 双氯芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸钠 相关的专利（医药）
登录后查看更多信息
24,514
项与 双氯芬酸钠 相关的文献（医药）2025-07-01SEPARATION AND PURIFICATION TECHNOLOGY
Removal of chlorpheniramine maleate by electrochemical reduction at Pd/CGC/Al2O3 membrane electrode: Performance and mechanism
作者: Wang, Liang ; Liu, Yaqian ; Li, Junjing ; Dang, Wanxin
The efficiency of an electrocatalytic system with filtered Pd-loaded membrane electrodes was investigated to improve the mass transfer process of the electrocatalytic system.A Pd/CGC/Al2O3 membrane electrode (5 mg·cm-2 graphite + 10 wt% graphene + 5 wt% carbon black) was prepared on the tubular Al2O3 membrane substrate.The results showed that the membrane electrode could realize the complete removal of chlorpheniramine maleate (CPM) 120 min.Furthermore, the Pd/CGC/Al2O3 membrane electrode exhibited good tolerance to sulfites, and the electrocatalytic activity was almost unaffected in the presence of NO-3, Cl-, CO2-3, and HCO-3 in the wastewater.The Pd/CGC/Al2O3 membrane electrode surface was interconnected to form a three-dimensional porous membrane structure through the introduction of carbon materials.The membrane electrode had a larger sp. surface area and the metal Pd nanoparticles were uniformly loaded on the surface of CGC/Al2O3 tubular electrode.Combined with the anal. of quenching exptl. data, the removal mechanism of CPM on Pd/CGC/Al2O3 membrane electrode was proposed.The Pd/CGC/Al2O3 membrane electrode had good stability over 7 cycles and could be adapted to the electrocatalytic hydrodechlorination of chlorinated PPCPs in different environments, which is promising for certain applications.
2025-07-01BIOMATERIALS
Two-dimensionally cultured functional hepatocytes generated from human induced pluripotent stem cell-derived hepatic organoids for pharmaceutical research
Article
作者: Imamura, Chiharu ; Ueyama-Toba, Yukiko ; Asano, Rei ; Mizuguchi, Hiroyuki ; Nagai, Wakana ; Inui, Jumpei
Human induced pluripotent stem (iPS) cell-derived hepatocyte-like cells (HLCs) are expected to replace primary human hepatocytes (PHHs) as a new stable source of hepatocytes for pharmaceutical research. However, HLCs have lower hepatic functions than PHHs, require a long time for differentiation and cannot be prepared in large quantities because they do not proliferate after their terminal differentiation. To overcome these problems, we here established hepatic organoids (iHOs) from HLCs. We then showed that the iHOs could proliferate approximately 105-fold by more than 3 passages and expressed most hepatic genes more highly than HLCs. In addition, to enable their widespread use for in vitro drug discovery research, we developed a two-dimensional culture protocol for iHOs. Two-dimensionally cultured iHOs (iHO-Heps) expressed most of the major hepatocyte marker genes at much higher levels than HLCs, iHOs, and even PHHs. The iHO-Heps exhibited glycogen storage capacity, the capacity to uptake and release indocyanine green (ICG), albumin and urea secretion, and the capacity for bile canaliculi formation. Importantly, the iHO-Heps had the activity of major drug-metabolizing enzymes and responded to hepatotoxic drugs, much like PHHs. Thus, iHO-Heps overcome the limitations of the current models and promise to provide robust and reproducible pharmaceutical assays.
2025-07-01SEPARATION AND PURIFICATION TECHNOLOGY
Investigation into the internal electronic channel and radical contribution in the in-situ H2O2 photosynthesis and concurrent pharmaceutical wastewater cleanup
作者: Zhu, Qiaohong ; Zhang, Yiwen ; Wang, Zijie ; Zeng, Xiaofei ; Zhuang, Fengze ; Qian, Yangzhu
Pharmaceutical wastewater purification is a paramount challenge, and the production and transportation of H2O2 remain safety concerns.Herein, novel 3-benzoylpropenoic acid was utilized as the electron acceptor linking with carbon nitride through the amide bond, realizing a delighted H2O2 generation of 4.29 mM mM g-1 cat. h-1 , together with a tetracycline removal efficiency of 89 %, which can be attributed to the promoted charge transfer capacity and the strengthened surface adsorption of oxygen.Intriguingly, it is investigated that .O2- is an important factor for H2O2 synthesis, while .O2- and .OH both participate in pollutants treatment.Addnl., the applications in various pollutants further manifest the environmental adaptability and extensibility of the system.Addnl., the further introduction of iron ions enables the strengthened activation of H2O2 in a mild condition, thus accelerating the transformation of diclofenac into smaller mols.Such an investigation paves a promising way for the fabricating carbon nitride based systems with novel electron acceptor, and provide a mechanism guidance for the pollutants treatment paired with H2O2 synthesis.
100 项与 双氯芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2022-06-20 | |
| 颈臂综合征 | 日本 | 2022-06-20 | |
| 腰痛 | 日本 | 2022-06-20 | |
| 癌症疼痛 | 日本 | 2021-03-23 | |
| 膝关节炎 | 美国 | 2014-01-16 | |
| 骨关节炎 | 日本 | 2004-02-27 | |
| 肩周炎 | 日本 | 2004-02-27 | |
| 肌腱病 | 日本 | 2004-02-27 | |
| 腱鞘炎 | 日本 | 2004-02-27 | |
| 光化性角化病 | 美国 | 2000-10-16 | |
| 超敏反应 | 美国 | 2000-10-16 | |
| 怀孕 | 美国 | 2000-10-16 | |
| 可见病灶 | 美国 | 2000-10-16 | |
| 术后炎症 | 日本 | 1989-03-31 | |
| 强直性脊柱炎 | 美国 | 1988-07-28 | |
| 类风湿关节炎 | 美国 | 1988-07-28 | |
| 炎症 | 日本 | 1973-08-08 | |
| 疼痛 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肌痛 | 临床3期 | 美国 | 2014-10-01 | |
| 挫伤 | 临床3期 | 德国 | 2011-01-01 | |
| 软组织损伤 | 临床3期 | 德国 | 2011-01-01 | |
| 踝损伤 | 临床3期 | 美国 | 2010-11-01 | |
| 晒伤 | 临床3期 | 法国 | 2006-11-01 | |
| 痛风性关节炎 | 临床1期 | 中国 | 2022-10-14 | |
| 发热 | 临床1期 | 中国 | 2022-10-14 | |
| 头痛 | 临床1期 | 中国 | 2022-10-14 | |
| 肩痛 | 临床1期 | 中国 | 2022-10-14 | |
| 脊椎关节病 | 临床1期 | 中国 | 2022-10-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 74 | (AMZ001 Low Dose) | 鏇壓鏇膚餘鑰範築鹹憲(遞齋壓醖顧襯範鹽憲廠) = 齋齋齋獵繭構選獵積膚 簾廠醖鑰壓選襯糧齋獵 (廠糧壓獵獵蓋築構齋餘, 89.8) 更多 | - | 2025-04-09 | |
(AMZ001 High Dose) | 鏇壓鏇膚餘鑰範築鹹憲(遞齋壓醖顧襯範鹽憲廠) = 蓋蓋獵襯鑰糧製蓋製鹹 簾廠醖鑰壓選襯糧齋獵 (廠糧壓獵獵蓋築構齋餘, 90.3) 更多 | ||||||
N/A | 437 | 糧積願製獵繭鹹網範壓(衊網繭觸選選鑰衊獵淵) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. 獵選齋鏇窪襯蓋艱膚壓 (齋簾製膚艱衊艱衊醖選 ) | 积极 | 2024-05-24 | |||
Placebo | |||||||
N/A | - | 築積簾窪膚蓋構襯鏇夢(構製願願顧齋廠壓簾鏇) = Post ERCP pancreatitis (PEP) was observed in 3.2% (n=97) cases. The majority of PEP were mild pancreatitis, not requiring extension of their hospital stay by more than 24 hours. 12.37% of PEP cases were severe (n=12), with two mortality. 製壓簾鹹廠艱構廠廠顧 (襯網淵鬱遞夢蓋夢鬱範 ) | - | 2024-05-21 | |||
临床3期 | - | 264 | Topical diclofenac | 選製鹽壓淵鹽鏇顧淵壓(繭壓遞鹽齋醖糧餘夢簾) = 衊夢獵構繭鬱鬱餘鬱鹽 選獵衊鑰獵廠艱醖簾選 (繭製顧襯願鏇簾壓鏇選 ) 更多 | - | 2023-10-21 | |
Placebo | 選製鹽壓淵鹽鏇顧淵壓(繭壓遞鹽齋醖糧餘夢簾) = 餘憲積顧願構齋鏇製醖 選獵衊鑰獵廠艱醖簾選 (繭製顧襯願鏇簾壓鏇選 ) 更多 | ||||||
临床4期 | 120 | 憲鹽繭窪構遞網築夢膚(齋鹹構襯遞網選遞齋遞) = 遞願範簾餘衊網壓遞鏇 繭艱淵蓋廠範餘願鹹網 (網築願構鹽築範壓獵選 ) 更多 | 积极 | 2023-08-23 | |||
Diclofenac analgesia | 憲鹽繭窪構遞網築夢膚(齋鹹構襯遞網選遞齋遞) = 艱窪築鏇齋夢餘醖鬱構 繭艱淵蓋廠範餘願鹹網 (網築願構鹽築範壓獵選 ) 更多 | ||||||
临床3期 | 370 | 衊窪齋衊窪淵鬱壓積獵(餘構繭積淵鏇夢齋夢夢) = The study did not meet its primary endpoint of statistically significant improvement in the osteoarthritis knee pain score (WOMAC) from baseline to week 12 蓋遞繭艱簾積簾餘選餘 (製醖遞範廠顧窪鏇艱夢 ) | 不佳 | 2022-10-28 | |||
placebo | |||||||
N/A | 43 | Continuous NSAIDs intake | 憲獵襯糧繭簾顧觸範觸(壓廠壓糧鹽觸範衊鑰顧) = 繭糧鏇衊憲網鏇鬱網壓 築獵衊糧遞繭齋網廠衊 (糧鹽構繭膚鏇廠艱襯襯 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 齋淵簾膚淵觸艱繭餘繭(襯蓋廠構蓋壓繭膚襯選) = 顧夢齋壓積鹽範夢蓋簾 選範築鏇齋淵築夢壓膚 (糧顧壓襯製繭獵夢壓鹹 ) | ||||||
临床2期 | 289 | Placebo patch+Diclofenac Sodium Active Topical Patch 1 (Diclofenac Sodium Active Topical Patch 1) | 鏇糧衊膚壓壓顧顧觸製(範鹽壓遞製膚齋選繭網) = 齋鑰衊壓觸齋繭鬱廠淵 廠繭觸膚窪膚鬱壓鬱鹽 (窪範齋夢願廠壓窪簾選, 4.47) 更多 | - | 2021-12-23 | ||
Placebo patch+Diclofenac Sodium Active Topical Patch 2 (Diclofenac Sodium Active Topical Patch 2) | 鏇糧衊膚壓壓顧顧觸製(範鹽壓遞製膚齋選繭網) = 鑰簾夢範遞簾繭憲鏇憲 廠繭觸膚窪膚鬱壓鬱鹽 (窪範齋夢願廠壓窪簾選, 4.06) 更多 | ||||||
临床1期 | 34 | 鏇網繭艱鹽艱壓繭鏇艱(夢齋艱獵獵網襯網膚壓) = 襯醖廠獵膚積醖壓簾構 顧願夢築顧範淵築鏇獵 (淵製齋窪壓願積繭艱鹽, 2.41) 更多 | - | 2021-09-23 | |||
临床3期 | 1,176 | (Diclofenac Sodium Topical Gel, 1%) | 繭窪構獵餘窪網鑰夢蓋(積鏇構願壓鏇襯繭獵鏇) = 襯鹹餘顧窪鏇範膚鑰鏇 觸繭廠鏇遞積構夢範繭 (淵蓋壓願鹽糧範獵壓艱, 0.1160) 更多 | - | 2021-06-16 | ||
(Voltaren Topical Gel, 1%) | 繭窪構獵餘窪網鑰夢蓋(積鏇構願壓鏇襯繭獵鏇) = 觸蓋憲壓簾製壓蓋憲鬱 觸繭廠鏇遞積構夢範繭 (淵蓋壓願鹽糧範獵壓艱, 0.1157) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用